"During the quarter we achieved several significant milestones, including receipt of CE Mark for our novel xTAG Gastrointestinal Pathogen Panel, the acquisition of EraGen Biosciences, and the expansion of our distribution channel for MAGPIX," added Balthrop. "These accomplishments will help ensure that Luminex delivers high performance solutions to our customers and long term value for our shareholders," Balthrop concluded. REVENUE SUMMARY(in thousands, except percentages)Three Months EndedJune 30,Variance20112010($)(%)(unaudited)System sales
9,2617,4391,82224%All other revenue
4,39643%Six Months EndedJune 30,Variance20112010($)(%)(unaudited)System sales
18,84515,0993,74625%All other revenue
24,41937%Consolidated revenue for the second quarter of 2011 was $47.6 million, a 43% increase over consolidated revenue of $33.2 million for the second quarter of 2010. GAAP net income for the second quarter of 2011 was $4.6 million, or $0.11 per diluted share, compared with GAAP net income of $0.9 million, or $0.02 per diluted share, for the prior year period. Included in SG&A expenses for the current quarter are approximately $1.3 million o
|SOURCE Luminex Corporation|
Copyright©2010 PR Newswire.
All rights reserved